AGM/EGMJun 12, 2026, 04:07 PM
Dare Bioscience Stockholders Approve 2022 Plan Amendment, Equity Line
AI Summary
Dare Bioscience, Inc. held its 2026 annual meeting of stockholders, where several key proposals were approved. Stockholders voted to amend the 2022 Stock Incentive Plan, increasing the number of shares available for issuance by 1,500,000. Additionally, directors were elected, the independent auditor was ratified, and the potential future issuance of shares under an existing equity line was approved. The board also determined to hold an advisory vote on executive compensation annually.
Key Highlights
- Stockholders approved an amendment to the 2022 Stock Incentive Plan, increasing shares available by 1,500,000.
- The 2022 Plan Amendment was approved with 3,497,228 votes for and 609,746 against.
- Gregory W. Matz and Sabrina Martucci Johnson were elected as Class III directors with 3,752,211 and 3,848,085 votes respectively.
- Haskell & White LLP was ratified as the independent auditor for 2026 with 7,754,883 votes for.
- Stockholders approved, on an advisory basis, executive compensation with 3,625,596 votes for.
- The board determined to hold an advisory vote on executive compensation annually, following 3,684,058 votes for 'Every year'.
- Stockholders approved the potential future issuance of shares under the equity line with Lincoln Park Capital Fund, LLC with 3,771,709 votes for.
Price Impact
More from DARE